LabStyle Innovations' Dario Blood Glucose Monitoring System Online e-Store and Membership Program Live in USA
Poster: SySAdmin
Posted on March 15, 2016 at 7:35:01 AM
LabStyle Innovations' Dario Blood Glucose Monitoring System Online e-Store and Membership Program Live in USA
World's largest glucose monitoring market gets user-centric mHealth product that brings diabetes management into the digital age
CAESAREA, Israel, March 15, 2016 /PRNewswire/ --
LabStyle Innovations Corp [http://www.mydario.com ]. (NASDAQ: DRIO), developer of the
Dario(TM) Blood Glucose Monitoring System, announced today the national availability of
Dario in the U.S. The U.S. rollout follows the U.S. Food and Drug Administration's 510(k)
clearance of the Dario in December 2015. The Dario made its U.S. debut at Medtrade
[http://www.medtrade.com/spring/show/about-the-show.shtml ]'s home medical
equipment/durable medical equipment trade show on February 29th through March 2nd in Las
Vegas, where it was well received by industry participants and distributors interested in
selling the product to their customer base.
Direct-to-consumer sales through LabStyle's U.S. website at usa.mydario.com/shop
[http://usa.mydario.com/shop ] are now available and supported through a U.S. based
customer service center and hotline. LabStyle's membership-based pricing for
direct-to-consumer test strip sales offers users a very cost-effective and convenient
solution. The Dario App [https://itunes.apple.com/il/app/dario/id571322125?mt=8 ] is now
also available through the App Store and ready for download by users across the U.S. Sales
through various non-exclusive third party distributors and medical equipment suppliers are
anticipated over the first half of 2016.
Through its U.S. headquarters in Massachusetts, the Company is working with insurers
to establish reimbursement and arrange agreements with distributors. Product orders for
the U.S. market are being processed and shipped through a fulfillment center in
California.
"The U.S. is the world's largest market for glucose monitoring and the launch of
national availability represents a transformative achievement not only for Dario, but more
importantly for users," said Erez Raphael, Chairman and CEO of LabStyle Innovations.
"Our unique ability to deliver a user-centric approach to monitoring glucose levels
and other important behavioral factors will help usher in a new era for diabetes
management in the U.S., delivering significant value to users, healthcare providers and
the entire American healthcare system," added Todd Durniak, LabStyle's Executive Vice
President and General Manager for North America.
The Dario Blood Glucose Monitoring System consists of an all-in-one Smart Meter that
plugs directly into smartphones coupled with a robust, real-time mobile app, that allows
users to track and monitor data such as: blood glucose measurements, carbs and insulin
intake, as well as physical activity directly on their mobile devices, making diabetes
data management much simpler. Additionally, users can share this data with their community,
family and medical staff.
The Dario app integrates with popular apps such as RunKeeper, helping diabetics better
manage exercise and fitness activities, and FatSecret, which allows for better food intake
management. Instantly generated, personalized reports help users better understand why
their blood glucose levels may change.
In keeping with Dario's user-centricity, the company has also focused on a new
business model that will revolutionize the way people with diabetes acquire strips.
Dario's exclusive membership program will allow people to sign up to a simple and
hassle-free program which will deliver the right quantity of strips to their door, every
90 days at competitive prices. Â
Dario is a leading pocket-sized all-in-one diabetes management solution that provides
users all over the world with important disease management features such as emergency
hypoglycemia contacts, actionable insights and easy information sharing with medical
staff. This technology is now available for people with diabetes in the USA.
About the Dario Â
The Dario Blood Glucose Monitoring System is intended for the quantitative measurement
of glucose (sugar) in fresh capillary whole blood. The Dario is intended for self-testing
outside the body (in vitro diagnostic use) by people with diabetes at home to monitor the
effectiveness of diabetes control.
The Dario Blood Glucose Monitoring System consists of a device housing that includes a
blood glucose meter and lancing device. The system also includes test strips, lancets,
control solutions and a mobile application. The Dario meter does not require coding or
separate batteries. The Dario meter is powered via the 3.5mm audio headphone jack of the
smart mobile device. Users are instructed to insert the test strip into the meter, apply
the blood or control solution to the test strip, after which the meter will process the
test in approximately six (6) seconds and display the test result on the smart mobile
device screen via the mobile application.
The Dario Blood Glucose Monitoring System uses Apple's iOS smart mobile device
technology to view the glucose test results via a mobile application. This application is
available for download via the smart mobile device's application store.
About LabStyle InnovationsÂ
LabStyle Innovations Corp. (NASDAQ:DRIO) creates innovative mobile and digital tools
that empower and engage users to lead healthier lives. LabStyle's "Real time. Real
improvements. Real People." approach and strategy is positioning the company as a major
player in the mHealth industry. LabStyle's flagship product is the Dario(TM) Blood Glucose
Monitoring System. Dario(TM) received U.S. FDA clearance in December 2015 and received
Europe's CE mark certification in September 2013.
For more information, the content of which is not part of this press release:
http://www.mydario.com and http://mydario.investorroom.com.
Cautionary Note Regarding Forward-Looking Statements Â
This news release and the statements of representatives and partners of LabStyle
Innovations Corp. (the "Company") related thereto contains or may contain forward-looking
statements within the meaning of the Private Securities Litigation Reform Act of 1995.
Statements that are not statements of historical fact may be deemed to be forward-looking
statements. Without limiting the generality of the foregoing, words such as "plan,"
"project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend,
" "could," "estimate" or "continue" are intended to identify forward-looking statements.
For example, the Company is using forward-looking statements when the Company says that
sales through various non-exclusive third party distributors and medical equipment
suppliers are anticipated over the first half of 2016 and that the Company is working with
insurers to establish reimbursement and arranging agreements with distributors. Readers
are cautioned that certain important factors may affect the Company's actual results and
could cause such results to differ materially from any forward-looking statements that may
be made in this news release. Factors that may affect the Company's results include, but
are not limited to, regulatory approvals, product demand, market acceptance, impact of
competitive products and prices, product development, commercialization or technological
difficulties, the success or failure of negotiations and trade, legal, social and economic
risks, and the risks associated with the adequacy of existing cash resources. Additional
factors that could cause or contribute to differences between the Company's actual results
and forward-looking statements include, but are not limited to, those risks discussed in
the Company's filings with the U.S. Securities and Exchange Commission. Readers are
cautioned that actual results  may differ significantly from those set forth in the
forward-looking statements. The Company undertakes no obligation to publicly update any
forward-looking statements, whether as a result of new information, future events or
otherwise, except as required by applicable law.
Â
Contacts:Â
Press and Investor RelationsÂ
Brenda ZeitlinÂ
LabStyle InnovationsÂ
+1-800-896-9062Â
Brenda@mydario.comÂ
Â
LabStyle Innovations Corp.
World's largest glucose monitoring market gets user-centric mHealth product that brings diabetes management into the digital age
CAESAREA, Israel, March 15, 2016 /PRNewswire/ --
LabStyle Innovations Corp [http://www.mydario.com ]. (NASDAQ: DRIO), developer of the
Dario(TM) Blood Glucose Monitoring System, announced today the national availability of
Dario in the U.S. The U.S. rollout follows the U.S. Food and Drug Administration's 510(k)
clearance of the Dario in December 2015. The Dario made its U.S. debut at Medtrade
[http://www.medtrade.com/spring/show/about-the-show.shtml ]'s home medical
equipment/durable medical equipment trade show on February 29th through March 2nd in Las
Vegas, where it was well received by industry participants and distributors interested in
selling the product to their customer base.
Direct-to-consumer sales through LabStyle's U.S. website at usa.mydario.com/shop
[http://usa.mydario.com/shop ] are now available and supported through a U.S. based
customer service center and hotline. LabStyle's membership-based pricing for
direct-to-consumer test strip sales offers users a very cost-effective and convenient
solution. The Dario App [https://itunes.apple.com/il/app/dario/id571322125?mt=8 ] is now
also available through the App Store and ready for download by users across the U.S. Sales
through various non-exclusive third party distributors and medical equipment suppliers are
anticipated over the first half of 2016.
Through its U.S. headquarters in Massachusetts, the Company is working with insurers
to establish reimbursement and arrange agreements with distributors. Product orders for
the U.S. market are being processed and shipped through a fulfillment center in
California.
"The U.S. is the world's largest market for glucose monitoring and the launch of
national availability represents a transformative achievement not only for Dario, but more
importantly for users," said Erez Raphael, Chairman and CEO of LabStyle Innovations.
"Our unique ability to deliver a user-centric approach to monitoring glucose levels
and other important behavioral factors will help usher in a new era for diabetes
management in the U.S., delivering significant value to users, healthcare providers and
the entire American healthcare system," added Todd Durniak, LabStyle's Executive Vice
President and General Manager for North America.
The Dario Blood Glucose Monitoring System consists of an all-in-one Smart Meter that
plugs directly into smartphones coupled with a robust, real-time mobile app, that allows
users to track and monitor data such as: blood glucose measurements, carbs and insulin
intake, as well as physical activity directly on their mobile devices, making diabetes
data management much simpler. Additionally, users can share this data with their community,
family and medical staff.
The Dario app integrates with popular apps such as RunKeeper, helping diabetics better
manage exercise and fitness activities, and FatSecret, which allows for better food intake
management. Instantly generated, personalized reports help users better understand why
their blood glucose levels may change.
In keeping with Dario's user-centricity, the company has also focused on a new
business model that will revolutionize the way people with diabetes acquire strips.
Dario's exclusive membership program will allow people to sign up to a simple and
hassle-free program which will deliver the right quantity of strips to their door, every
90 days at competitive prices. Â
Dario is a leading pocket-sized all-in-one diabetes management solution that provides
users all over the world with important disease management features such as emergency
hypoglycemia contacts, actionable insights and easy information sharing with medical
staff. This technology is now available for people with diabetes in the USA.
About the Dario Â
The Dario Blood Glucose Monitoring System is intended for the quantitative measurement
of glucose (sugar) in fresh capillary whole blood. The Dario is intended for self-testing
outside the body (in vitro diagnostic use) by people with diabetes at home to monitor the
effectiveness of diabetes control.
The Dario Blood Glucose Monitoring System consists of a device housing that includes a
blood glucose meter and lancing device. The system also includes test strips, lancets,
control solutions and a mobile application. The Dario meter does not require coding or
separate batteries. The Dario meter is powered via the 3.5mm audio headphone jack of the
smart mobile device. Users are instructed to insert the test strip into the meter, apply
the blood or control solution to the test strip, after which the meter will process the
test in approximately six (6) seconds and display the test result on the smart mobile
device screen via the mobile application.
The Dario Blood Glucose Monitoring System uses Apple's iOS smart mobile device
technology to view the glucose test results via a mobile application. This application is
available for download via the smart mobile device's application store.
About LabStyle InnovationsÂ
LabStyle Innovations Corp. (NASDAQ:DRIO) creates innovative mobile and digital tools
that empower and engage users to lead healthier lives. LabStyle's "Real time. Real
improvements. Real People." approach and strategy is positioning the company as a major
player in the mHealth industry. LabStyle's flagship product is the Dario(TM) Blood Glucose
Monitoring System. Dario(TM) received U.S. FDA clearance in December 2015 and received
Europe's CE mark certification in September 2013.
For more information, the content of which is not part of this press release:
http://www.mydario.com and http://mydario.investorroom.com.
Cautionary Note Regarding Forward-Looking Statements Â
This news release and the statements of representatives and partners of LabStyle
Innovations Corp. (the "Company") related thereto contains or may contain forward-looking
statements within the meaning of the Private Securities Litigation Reform Act of 1995.
Statements that are not statements of historical fact may be deemed to be forward-looking
statements. Without limiting the generality of the foregoing, words such as "plan,"
"project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend,
" "could," "estimate" or "continue" are intended to identify forward-looking statements.
For example, the Company is using forward-looking statements when the Company says that
sales through various non-exclusive third party distributors and medical equipment
suppliers are anticipated over the first half of 2016 and that the Company is working with
insurers to establish reimbursement and arranging agreements with distributors. Readers
are cautioned that certain important factors may affect the Company's actual results and
could cause such results to differ materially from any forward-looking statements that may
be made in this news release. Factors that may affect the Company's results include, but
are not limited to, regulatory approvals, product demand, market acceptance, impact of
competitive products and prices, product development, commercialization or technological
difficulties, the success or failure of negotiations and trade, legal, social and economic
risks, and the risks associated with the adequacy of existing cash resources. Additional
factors that could cause or contribute to differences between the Company's actual results
and forward-looking statements include, but are not limited to, those risks discussed in
the Company's filings with the U.S. Securities and Exchange Commission. Readers are
cautioned that actual results  may differ significantly from those set forth in the
forward-looking statements. The Company undertakes no obligation to publicly update any
forward-looking statements, whether as a result of new information, future events or
otherwise, except as required by applicable law.
Â
Contacts:Â
Press and Investor RelationsÂ
Brenda ZeitlinÂ
LabStyle InnovationsÂ
+1-800-896-9062Â
Brenda@mydario.comÂ
Â
LabStyle Innovations Corp.